PARIS & WALTHAM, Mass.–(BUSINESS WIRE)– Echosens, een hoogtechnologisch bedrijf dat de FibroScan®-portfolio van oplossingen aanbiedt, is verheugd om zijn 20e opeenvolgende jaar als pionier op het gebied van leverdiagnose en -beheer te vieren. Wereldwijd erkend als de referentie voor de beoordeling van leverfibrose en leversteatose, met meer dan 3.000+ peer-reviewed publicaties en 140+ internationale richtlijnen, blijft Echosens een ongeëvenaarde toewijding aan innovatie tonen. Alleen al in het afgelopen jaar lanceerde Echosens drie nieuwe wereldwijde producten, allemaal zorgvuldig ontworpen om de algehele FibroScan-ervaring te optimaliseren.

Een jaar geleden lanceerde Echosens hun vlaggenschip en meest geavanceerde product, de FibroScan Expert 630. Dit apparaat is de complete niet-invasieve oplossing voor de behandeling van leverziekte, mogelijk gemaakt door leverstijfheidsmeting (LSM door VCTE) CAP en miltstijfheidsmeting (SSM door VCTE) als onderdeel van een algehele beoordeling van de lever.

Innovative New Products and Technology Advancing Worldwide Liver Disease Management Highlight Echosens 20th Anniversary

PARIS & WALTHAM, Mass.–(BUSINESS WIRE)– Echosens, a high-technology company offering the FibroScan^® portfolio of solutions, is pleased to celebrate its 20th consecutive year pioneering the field of liver diagnosis and management. Recognized worldwide as the reference for liver fibrosis and liver steatosis assessment, with more than 3,000+ peer-reviewed publications and 140+ international guidelines, Echosens continues to show an unparalleled commitment to innovation. In the past year alone Echosens launched three new global products all carefully designed to optimize the overall FibroScan experience.

A year ago, Echosens launched their flagship and most advanced product, the FibroScan Expert 630. This device is the complete non-invasive solution for liver disease management, powered by liver stiffness measurement (LSM by VCTE) CAP and spleen stiffness measurement (SSM by VCTE) as part of an overall assessment of the liver.

Echosens then launched SmartExam software, which unlocks three key benefits for users: improved reliability in the diagnosis and monitoring of steatosis with continuous CAP; extended usage among severely obese patients with deeper assessment of liver fibrosis and steatosis; and task automation features that enable physicians to dedicate more time to patient care.

Recently, Echosens launched FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients. Included on the free myFibroScan app, users can now assess a patient’s liver health in just a few clicks, making interpreting results quicker and easier than ever.

“Our long-term commitment to innovation optimizes the FibroScan portfolio of solutions, representing a major step toward winning the worldwide battle against liver disease,” says Dominique Legros, Group CEO, Echosens. “We’re highly grateful to our team leaders and champions for continuing to challenge the status quo in improving the management of silent, underdiagnosed chronic liver disease, which includes NAFLD and its more severe form nonalcoholic steatohepatitis (NASH). A number of chronic liver diseases can be reversible if diagnosed early.”

He points to the FibroScan Expert 630 as an innovative tool designed to expand clinical capabilities in liver health assessment with the addition of SSM by VCTE. This tool potentially supplies a cost-effective, non-invasive modality for spleen and liver stiffness measurements that may be used as an aid in the diagnosis, monitoring and clinical management of adult patients with liver disease.

For more than two decades, Echosens has generated robust clinical data that is extremely valuable in helping providers, benefits decision-makers and payers understand how a point-of-care examination can improve the quality of specialist referrals – reducing waste from unnecessary and often invasive testing. This was validated in an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) and published in the September 2021 issue of the American Journal of Managed Care.

“Furthermore, the National Institute for Health and Care Excellence (NICE), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary care setting,” says Legros. “Additionally, new guidelines from the European Association for the Study of the Liver (EASL), a professional association for those researching liver disease, outlined an unprecedented level of recommendation for Echosens’ solutions.”

Jon Gingrich, CEO, Echosens North America, states, “During our anniversary year, it is gratifying to highlight the exciting technological advances we have developed and introduced to the healthcare industry. We have demonstrated our commitment to innovation and value in the field, reflected by the essential and actionable data to support and advance liver health management.”

Listen to episodes of eHealth Radio Network, featuring some of today’s leading innovators in healthcare and wellness.

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan^®, the non-invasive solution for comprehensive management of liver health. FibroScan^® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines. Echosens has made FibroScan^® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/

Contacts

Media:
Brittany Tedesco

CPR Communications

btedesco@cpronline.com
201.641.1911 x 14